Medical Oncology

, 30:645 | Cite as

Correlation of EGFR mutation and predominant histologic subtype according to the new lung adenocarcinoma classification in Chinese patients

  • Zhengbo Song
  • Huineng Zhu
  • Zhenying Guo
  • Wei Wu
  • Wenyong Sun
  • Yiping Zhang
Short Communication


A new lung adenocarcinoma classification proposed by the International Association for the Study of Lung Cancer, American Thoracic Society, and European Respiratory Society (IASLC/ATS/ERS) has recently been published. However, the relationship between EGFR mutations and subtype of adenocarcinoma remains unclear. A total of 161 surgically resected lung adenocarcinomas in Zhejiang Cancer Hospital were reviewed using the new classification system. Epidermal growth factor receptor (EGFR) mutations were observed in 67 cases (41.6 %). EGFR mutations were found to be closely associated with the micropapillary predominant subtype (P = 0.0068) and lepidic component (P = 0.005). The frequency of EGFR mutation was found to be lower in the solid predominant subtype than other subtype (P = 0.04). In conclusion, histologic subtyping was found to be associated with EGFR mutations. The EGFR mutation frequency of micropapillary and lepidic predominant subtypes was found to be more pronounced than that of other subtypes.


Non-small cell lung cancer Adenocarcinoma subtype EGFR mutation 



This work was supported by grants from the Natural Science Foundation of Zhejiang (No. LY13H160024), the Medical Scientific Research Foundation of Zhejiang Province (Nos. 2013KYB049, 2012KYA023) and fund of development center for medical science and technology ministry of health (W2012FZ134).

Conflict of interest

The authors have no conflicts of interest.


  1. 1.
    Siegel R, Ward E, et al. Cancer statistics 2011. CA Cancer J Clin. 2011;61:212–36.PubMedCrossRefGoogle Scholar
  2. 2.
    Travis WD, et al. The new IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol. 2011;6:244–85.PubMedCrossRefGoogle Scholar
  3. 3.
    Maemondo M, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362:2380–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Mitsudomi T, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11:121–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Shim HS, et al. Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor receptor mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society lung adenocarcinoma classification. Arch Pathol Lab Med. 2011;135:1329–34.PubMedCrossRefGoogle Scholar
  6. 6.
    Sun PL, et al. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol. 2012;7:323–30.PubMedCrossRefGoogle Scholar
  7. 7.
    Zhang Y, et al. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis. Clin Cancer Res. 2012;18:1947–53.PubMedCrossRefGoogle Scholar
  8. 8.
    Ang DC et al. Characteristic morphology and immunoprofile of lung adenocarcinoma with KRAS mutations: propensity for solid growth pattern and correlation with TTF-1 expression. Mod Pathol. 2010;23:396A (suppl; abstr 1769).Google Scholar
  9. 9.
    Russell PA, et al. Correlation of mutation status and survival with predominant histologic subtype according to the New IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients. J Thorac Oncol. 2013;8:461–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Department of ChemotherapyZhejiang Cancer HospitalHangzhouPeople’s Republic of China
  2. 2.Key Laboratory Diagnosis and Treatment Technology on Thoracic OncologyHangzhouChina
  3. 3.Department of PathologyZhejiang Cancer HospitalHangzhouChina

Personalised recommendations